Study of Ravulizumab in Pediatric Participants With HSCT-TMA

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT04557735
Trial Phases:	Phase III	Protocol IDs:	ALXN1210-TMA-314 (primary) NCI-2021-04301 2020-000761-16
Eligibility:	0 - 17 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Alexion Pharmaceuticals, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04557735

Summary

This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of
ravulizumab administered by intravenous infusion to pediatric participants, from 1 month
to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a
26-week off-treatment follow-up period.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.